Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15352136 | 0.86 | USP2 (0.44) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL25905171 | 0.86 | SMN1; SMN2 (0.44) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL25678515 | 0.86 | TLR8 (0.46) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL6661328 | 0.86 | USP2 (0.44) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL15435945 | 0.86 | SMN1; SMN2 (0.44) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL22262696 | 0.86 | USP2 (0.44) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL23251655 | 0.85 | USP2 (0.46) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL20572924 | 0.84 | USP2 (0.43) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL25325699 | 0.84 | USP2 (0.43) | TLR8USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL21855435 | 0.84 | USP2 (0.43) | TLR8USP2SMN1; SMN2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007053618-A1 | PRODRUGS OF MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070105836-A1 | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders | ACADIA PHARMACEUTICALS INC. | 2007-05-10 | — | — | US | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105836-A1 | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders | CHRM4, CHRM3, CHRM5 | TLR8 2079/4885USP2 2273/4885SMN1; SMN2 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.